Aims/hypothesis
Plasma soluble receptor for AGE (sRAGE) may reflect the activity of the AGE–RAGE axis, which has been proposed as a potential
mechanism linking hyperglycaemia to vascular complications in diabetes. We have therefore investigated: (1) whether sRAGE
is associated with greater prevalence of cardiovascular disease (CVD) and microvascular complications in type 1 diabetic individuals;
and (2) the extent to which any such associations are explained by markers of endothelial and renal dysfunction and inflammation.
Methods
The study included 477 individuals (234 women; mean age 42 ± 10 [SD] years) from the EURODIAB Prospective Complications Study.
We used linear regression analyses to investigate the differences in sRAGE levels between individuals with and without vascular
complications. All analyses were adjusted for age, sex, HbA1c, duration of diabetes and other risk factors.
Results
Individuals with CVD (n = 116) had higher levels of sRAGE than those without CVD or any microvascular complications (n = 178): β = 0.15 (95% CI 0.04–0.27). Further adjustments for markers of endothelial (β = 0.13 [0.02–0.24]) and renal dysfunction (β = 0.10 [−0.01, 0.20]) and inflammation (β = 0.12 [0.01–0.23]) attenuated these differences; altogether these variables explained about 50% of the association between
sRAGE and prevalent CVD. sRAGE levels tended to be higher in the presence and across the levels of severity of albuminuria
(p for trend = 0.087) and retinopathy (p for trend = 0.057); adjustments for endothelial and renal dysfunction and inflammation also attenuated these differences.
Conclusions/interpretation
sRAGE is associated with greater prevalence of CVD in type 1 diabetic individuals, and these associations may be partly explained
by endothelial and renal dysfunction and low-grade inflammation.
Keywords Cardiovascular disease - Diabetes mellitus - Endothelial dysfunction - Inflammation - Microvascular complications - Renal dysfunction - Soluble receptor for advanced glycation end-products